2-(3,5-difluoroanilino)-1,4-naphthoquinone | 1276184-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(3,5-difluoroanilino)-1,4-naphthoquinone
• 英文别名: 2-((3,5-difluorophenyl)amino)naphthalene-1,4-dione；2-(3,5-Difluoroanilino)naphthalene-1,4-dione；2-(3,5-difluoroanilino)naphthalene-1,4-dione
• CAS: 1276184-20-3
• 化学式: C₁₆H₉F₂NO₂
• 分子量: 285.25
• InChiKey: RFZFJSSOVGAKMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,5-二氟苯胺 在 potassium carbonate 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 2-(3,5-difluoroanilino)-1,4-naphthoquinone
  参考文献：
  名称：

  Novel 2-Amino-1,4-Naphthoquinone Derivatives Induce A549 Cell Death through Autophagy

  摘要：

  合成了一系列可用作抗癌剂的 1,4-萘醌衍生物，并通过 X 射线衍射证实了化合物 5a 的晶体结构。化合物 5i 对 A549 细胞株具有显著的细胞毒性，IC50 为 6.15 μM。令人惊讶的是，在接下来的初步生物学实验中，我们发现化合物 5i 通过促进表皮生长因子受体（EGFR）的循环和信号转导，诱导了 A549 细胞的自噬，从而激活了 EGFR 信号通路。分子对接还确定了化合物 5i 与表皮生长因子受体酪氨酸激酶（PDB ID：1M17）的潜在结合模式。我们的研究为进一步研究和开发新型强效抗癌药物铺平了道路。

  DOI：

  10.3390/molecules28083289

文献信息

• Synthesis, spectral and electrochemical characterization of novel 2-(fluoroanilino)-1,4-naphthoquinones
  作者：Elisa Leyva、Lluvia I. López、Silvia E. Loredo-Carrillo、Margarita Rodríguez-Kessler、Antonio Montes-Rojas

  DOI：10.1016/j.jfluchem.2010.12.001

  日期：2011.2

  The preparation of novel 2-(fluoroanilino)-1,4-naphthoquinones is presented. It takes place under mild conditions by reacting the corresponding fluoroaniline and 1,4-naphthoquinone in the presence of a Lewis acid catalyst with strong oxidation properties such as CeCl3·7H2O. This preparation was also investigated under microwave irradiation. All 1,4-naphthoquinone derivatives were characterized by UV–Vis

  介绍了新型2-（氟苯胺基）-1,4-萘醌的制备。它是在温和的条件下，通过使相应的氟苯胺和1,4-萘醌在具有强氧化性能的路易斯酸催化剂（例如CeCl 3 ·7H 2 O）存在下反应来进行的。该制备方法也在微波辐射下进行了研究。所有1，4-萘醌衍生物均通过UV-Vis，IR，1 H和19 F NMR，MS和循环伏安法进行表征，以研究含氟取代基对其电子性能的影响。
• Compositions and methods for treatment of prostate carcinoma
  申请人：Pellficure Pharmaceuticals, Inc.

  公开号：US10093620B2

  公开（公告）日：2018-10-09

  Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

  本文公开了1,4-萘醌类似物、包括一种或多种此类1,4-萘醌类似物的药物组合物，以及用此类1,4-萘醌类似物治疗和/或改善与癌症（如前列腺癌）相关的疾病和/或病症的方法。还包括组合疗法，其中向患有癌症等疾病的受试者提供本文公开的 1,4-萘醌类似物和激素治疗剂。
• COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA
  申请人：Pellficure Pharmaceuticals, Inc.

  公开号：US20170283374A1

  公开（公告）日：2017-10-05

  Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
• Novel 2-Amino-1,4-Naphthoquinone Derivatives Induce A549 Cell Death through Autophagy
  作者：Hua-Yuan Tan、Feng-Ming Liang、Wen-Jing Zhang、Yi Zhang、Jun-Hao Cui、Yu-Yu Dai、Xue-Mei Qiu、Wen-Hang Wang、Yue Zhou、Dan-Ping Chen、Cheng-Peng Li

  DOI：10.3390/molecules28083289

  日期：——

  A series of 1,4-naphthoquinone derivatives containing were synthesized as anti-cancer agents and the crystal structure of compound 5a was confirmed by X-ray diffraction. In addition, the inhibitory activities against four cancer cell lines (HepG2, A549, K562, and PC-3) were tested, respectively, and compound 5i showed significant cytotoxicity on the A549 cell line with the IC50 of 6.15 μM. Surprisingly, in the following preliminary biological experiments, we found that compound 5i induced autophagy by promoting the recycling of EGFR and signal transduction in the A549 cell, resulting in the activation of the EGFR signal pathway. The potential binding pattern between compound 5i and EGFR tyrosine kinase (PDB ID: 1M17) was also identified by molecular docking. Our research paves the way for further studies and the development of novel and powerful anti-cancer drugs.

  合成了一系列可用作抗癌剂的 1,4-萘醌衍生物，并通过 X 射线衍射证实了化合物 5a 的晶体结构。化合物 5i 对 A549 细胞株具有显著的细胞毒性，IC50 为 6.15 μM。令人惊讶的是，在接下来的初步生物学实验中，我们发现化合物 5i 通过促进表皮生长因子受体（EGFR）的循环和信号转导，诱导了 A549 细胞的自噬，从而激活了 EGFR 信号通路。分子对接还确定了化合物 5i 与表皮生长因子受体酪氨酸激酶（PDB ID：1M17）的潜在结合模式。我们的研究为进一步研究和开发新型强效抗癌药物铺平了道路。